Get more replies from employers
Send a job-specific resume in minutes.
The Mayo Clinic Comprehensive Cancer Center in Jacksonville, FL invites applications for an open-rank faculty position in Artificial Intelligence with experience in Computational Biology and applications to Radiation Oncology.
We seek an investigator to lead AI tool development across translational and clinical research, guiding multidisciplinary teams and collaborating with Mayo Clinic Platform and heavy particle therapy initiatives.
Position Description
The Mayo Clinic Comprehensive Cancer Center (MCCCC) enterprise site in Jacksonville, Florida invites applications for an open-rank faculty position for an innovative and accomplished leader in Artificial Intelligence, with experience in Computational Biology preferred, and their application in the basic, translational and clinical research programs within Radiation Oncology.
We seek an exceptional investigator (scientist and/or physician) with expertise in artificial intelligence (AI) and its application in basic and translational biology and clinical decision making. The successful candidate will play a central role in advancing a rapidly growing, multidisciplinary heavy particle program focused on discovery science, translational innovation, and clinical impact.
A key component of this role will be developing artificial intelligence tools within some of the areas below including, but not limited to:
The investigator will:
The successful candidate will be a key driver in integrating artificial intelligence technologies into existing and emerging radiation oncology platforms, enabling novel approaches to heavy particle therapy.
Mayo Clinic and Mayo Clinic Comprehensive Cancer Center offer a highly collaborative and integrated academic medical center environment with expanding strengths in cell therapy, cancer immunotherapy, regenerative medicine, and translational science. Mayo Clinic and MCCCC have built a world-class research hub to transform cancer patient care through actionable target discovery and next-generation discovery and therapeutic platforms. These foundational platforms include Mayo Clinic Platform (www.mayoclinicplatform.org) which holds the fully digitized longitudinal patient records from 15M Mayo Clinic patients and 54M patients from across the nation and the globe with collaborating healthcare institutions, which facilitate research through development of longitudinal patient cohorts prior to and following disease diagnosis. Mayo Clinic has also developed very strong AI-driven discovery, translational, and clinical programs with exceptional “on premises” and cloud-based computational resources.
Mayo Clinic is committed to creating an inclusive and equitable environment, recognizing that diverse research teams drive more innovative solutions to complex biomedical challenges.
With 440 members and >1500 aligned cancer physicians working in six Cancer Research Programs (Cancer Prevention, Survivorship & Control; Cancer Risk Assessment, Early Detection & Interception; Cancer Genomics, Signaling, & Metastasis; Cancer Immunology & Immunotherapeutics; Novel Therapeutics & Therapeutic Modalities; Advanced Clinical Trials and Translational Sciences) and 15 Disease Groups focused on clinical trials, MCCCC is a global leader and represents the pinnacle of cancer care, research and education and training. Every year, across its three enterprise sites (Rochester, Minnesota; Phoenix and Scottsdale, Arizona; and Jacksonville, Florida), MCCCC physicians provide expert cancer diagnosis and treatment to more than 150,000 unique patients from across the nation and the globe.
To inspire hope and promote health and healing through integrated research, clinical practice, and education, centered around our primary value: the needs of the patient come first.
To be a global cancer authority: transforming cancer research and practice to assure that our discoveries, knowledge, and expertise are accessible to all, within and beyond our walls, at anyplace and anytime.
Over the past year, MCCCC has continued to achieve exceptional performance metrics, with high levels of cancer research funding (reporting $61.2M in annual peer-reviewed funding ($41.1M from NCI) and $98.7M in industry and non-peer reviewed funding). The Center currently has over 80 multi-investigator programmatic grants including 6 NCI Specialized Programs of Research Emphasis (SPORES): Myeloma, Ovarian Cancer, Breast Cancer, Liver/Hepatobiliary Cancers, Prostate Cancer, and Sarcoma. In 2025, clinical trial accrual has remained robust, reporting the Center’s highest accrual to therapeutic interventional trials: 2,624 (12% of newly registered cases), with 6,588 interventional accruals (30% of newly registered patients) and 10,367 non-interventional accruals. In 2025, MCCCC members published an exceptional number (1776) of peer-reviewed academic works, 24% of which were published in high impact journals.
Mayo Clinic is a premier, integrated academic medical center consistently ranked among the top hospitals in the nation. All campuses are experiencing strategic growth in cancer immunotherapy, drug discovery & development, regenerative medicine, and translational discovery science.
Located in the state-of-the-art Duan Family Building on Mayo Clinic Florida's campus, advanced 360-degree proton gantries and carbon fixed beam enable enhanced targeting of hard-to-treat cancers. These technologies help Mayo Clinic physicians conduct integrated therapy planning and simulation in conjunction with radiation oncology treatments.
To enhance the benefits of heavy particle therapy delivery, Mayo Clinic is partnering with a software development company to create an advanced treatment planning system that works with photon, proton and carbon ion therapies. This system, which is not typically available for most patients receiving radiation therapy, reduces the radiation dose sent to healthy tissue. It also provides real-time online adaptive treatment planning – adjusting each patient's plan daily based on tumor shrinkage or shifting.